Incidence of cotherapy
Before the listing of coxibs on the Ontario Drug Benefit Formulary in 2000, 21.6% of patients receiving conventional NSAIDs were coprescribed a GPA (proton pump inhibitor [PPI], or H2RA, with a small proportion receiving misoprostol). Following the introduction of the coxibs, the rate of coprescription of a GPA with traditional NSAIDs remained unchanged (22.0%), while only 6.8% of patients receiving rofecoxib were coprescribed a GPA. This change in practice was confirmed by a survey of 360 Canadian family physicians, which reported that 37% of patients receiving NSAIDs were coprescribed a GPA compared with only 6% of patients prescribed a coxib. In Ontario, the coprescription rate was 47% for NSAID- and 5% for coxib-takers, respectively. Buy cheap drugs online fast – buy clomiphene for you to enjoy a reliable pharmacy.
Health resources analysis
An analysis of health care resource use by subjects enrolled in the VIGOR study showed a potential cost savings among coxib users. Subjects in the rofecoxib arm required less gastroprotective therapy (23%), fewer upper gastrointestinal procedures (25%) and fewer hospitalizations (50%). A 12-week trial comprising 13,274 patients with osteoarthritis showed that hospitalization rates for upper gastrointestinal diagnoses were two to four times lower and fewer upper gastrointestinal-related health care resources were used by celecoxib-treated patients than by NSAID-treated patients.